JP7751582B2 - タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法 - Google Patents

タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法

Info

Publication number
JP7751582B2
JP7751582B2 JP2022538083A JP2022538083A JP7751582B2 JP 7751582 B2 JP7751582 B2 JP 7751582B2 JP 2022538083 A JP2022538083 A JP 2022538083A JP 2022538083 A JP2022538083 A JP 2022538083A JP 7751582 B2 JP7751582 B2 JP 7751582B2
Authority
JP
Japan
Prior art keywords
fluoro
thiadiazolidine
trione
hydroxy
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022538083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507774A5 (enExample
JP2023507774A (ja
Inventor
エリオット ピー． ファーニー
ルーホッラー カゼム シルーディ
チャオミン ション
キンウェイ チャン
マシュー オコナー
ジョフ ティー． ハルボルセン
ホンユ チャオ
クリスティーナ バウムガートナー
ジェニファー エム． フロスト
フィリップ アール． キム
ジェイソン アール． アボット
アンドリュー ボグダン
クリストス エコノム
シュエキン ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2023507774A publication Critical patent/JP2023507774A/ja
Publication of JP2023507774A5 publication Critical patent/JP2023507774A5/ja
Priority to JP2025159693A priority Critical patent/JP2026004380A/ja
Application granted granted Critical
Publication of JP7751582B2 publication Critical patent/JP7751582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2022538083A 2019-12-18 2020-12-18 タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法 Active JP7751582B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025159693A JP2026004380A (ja) 2019-12-18 2025-09-26 タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949613P 2019-12-18 2019-12-18
US62/949,613 2019-12-18
PCT/US2020/066104 WO2021127499A1 (en) 2019-12-18 2020-12-18 Protein tyrosine phosphatase inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025159693A Division JP2026004380A (ja) 2019-12-18 2025-09-26 タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2023507774A JP2023507774A (ja) 2023-02-27
JP2023507774A5 JP2023507774A5 (enExample) 2023-12-20
JP7751582B2 true JP7751582B2 (ja) 2025-10-08

Family

ID=74195125

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538083A Active JP7751582B2 (ja) 2019-12-18 2020-12-18 タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
JP2025159693A Pending JP2026004380A (ja) 2019-12-18 2025-09-26 タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025159693A Pending JP2026004380A (ja) 2019-12-18 2025-09-26 タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法

Country Status (8)

Country Link
US (1) US20230019236A1 (enExample)
EP (1) EP4077291A1 (enExample)
JP (2) JP7751582B2 (enExample)
CN (1) CN116348455A (enExample)
AU (1) AU2020407648A1 (enExample)
CA (1) CA3162069A1 (enExample)
MX (2) MX2022007441A (enExample)
WO (1) WO2021127499A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3908272B1 (en) 2019-01-09 2023-03-22 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-triiodothyronine (t3) for use in limiting microvascular obstruction
AU2020401376A1 (en) 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
CN118556055A (zh) * 2021-11-11 2024-08-27 卡里科生命科学有限责任公司 蛋白酪氨酸磷酸酶抑制剂及其使用方法
MX2024005658A (es) * 2021-11-11 2024-08-06 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
JP2025530135A (ja) * 2022-09-13 2025-09-11 カムクワット バイオサイエンシーズ インコーポレイテッド ベンゾ縮合ｎ－複素環及びその使用
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
TW202519514A (zh) 2023-07-14 2025-05-16 天主教魯汶大學 新穎化合物(一)
CN119818693A (zh) * 2023-10-13 2025-04-15 华东师范大学 一种用于前药给药系统的可裂解支链连接体化合物及其制备和应用
CN121627562A (zh) * 2024-09-04 2026-03-10 南京圣和药业股份有限公司 作为wrn抑制剂的化合物及其应用
WO2026112350A1 (en) * 2024-11-22 2026-05-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2026132150A1 (en) 2024-12-19 2026-06-25 Katholieke Universiteit Leuven Inhibitors of ptpn 2/ ptpn1 tyrosine phosphatase
WO2026132146A1 (en) 2024-12-19 2026-06-25 Katholieke Universiteit Leuven Inhibitors of ptpn 2/ ptpn1 tyrosine phosphatase
WO2026132149A1 (en) 2024-12-19 2026-06-25 Katholieke Universiteit Leuven Inhibitors of ptpn2 and/or ptpn1
WO2026132148A1 (en) 2024-12-19 2026-06-25 Katholieke Universiteit Leuven Inhibitors of ptpn2/ptpn1 tyrosine phosphatase
WO2026130528A1 (zh) * 2024-12-20 2026-06-25 杭州百新生物医药科技有限公司 Ptpn2/ptpn1抑制剂及其制备方法和医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518419A (ja) 2005-12-08 2009-05-07 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅ阻害剤としての１−オルトフルオロフェニル置換１，２，５−チアゾリジンジオン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212A (en) 1847-07-31 Richard m
US162A (en) 1837-04-17 Island
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
TWI888352B (zh) * 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
KR102983496B1 (ko) * 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518419A (ja) 2005-12-08 2009-05-07 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅ阻害剤としての１−オルトフルオロフェニル置換１，２，５−チアゾリジンジオン誘導体

Also Published As

Publication number Publication date
US20230019236A1 (en) 2023-01-19
MX2022007441A (es) 2022-09-02
WO2021127499A1 (en) 2021-06-24
CA3162069A1 (en) 2021-06-24
JP2023507774A (ja) 2023-02-27
JP2026004380A (ja) 2026-01-14
EP4077291A1 (en) 2022-10-26
CN116348455A (zh) 2023-06-27
AU2020407648A1 (en) 2022-06-30
MX2026004270A (es) 2026-05-04

Similar Documents

Publication Publication Date Title
JP7704787B2 (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
JP7617890B2 (ja) タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2026004380A (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
US20250122160A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения
RU2833220C2 (ru) Ингибиторы белковых тирозинфосфатаз и способы их применения

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250926

R150 Certificate of patent or registration of utility model

Ref document number: 7751582

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150